Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
基本信息
- 批准号:10085104
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
ABSTRACT
Bladder cancer (BCa) is one of the most common cancers in veterans. There is no significant improvement in
overall survival for advanced BCa over the last three decades. Immunotherapy with immune checkpoint
inhibitors showed promising anti-tumor activity in this disease. However, less than 20% of patients respond
to this treatment. Various strategies, including combination with other therapies, are being explored to
enhance the efficacy of immunotherapy. With the funding of the VA Career Development Award-2 and VA
Merit, we developed a BCa-specific PLZ4-nanoporphyrin (PNP) that combines imaging-guided
chemotherapy, photodynamic and photothermal therapies into a single platform. All three therapies have
been shown to potentiate immunotherapy with cancer vaccines. Here we propose to determine whether the
efficacy of immunotherapy with an immune checkpoint inhibitor can be enhanced via combining
immunotherapy with chemotherapy, photodynamic and photothermal therapies using PNP. Because PNP can
target the mouse BCa cell line MB49, we will first conduct the efficacy studies in immunocompetent mice
carrying MB49 syngeneic tumors.
Recently, we developed
humanized mice in which the immune cells of the
host mice are derived from humans. We will implant into these mice patient-derived xenografts (PDX) that are
developed from unselected and uncultured human patient cancer tissues in order to validate the MB49 cell
line studies in mice. We will then translate the studies into BCa transgenic mice to determine whether PNP
can potentiate immunotherapy. Mechanisms of resistance will also be studied. Since we have already held a
pre-IND (Investigational New Drug) consultation with the US Food and Drug Administration for PNP,
successful completion of this project can lead to a clinical trial to combine PNP with immunotherapy in BCa.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHONG-XIAN PAN其他文献
CHONG-XIAN PAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHONG-XIAN PAN', 18)}}的其他基金
BCCMA: Translational research to improve the care of advanced bladder cancer
BCCMA:改善晚期膀胱癌护理的转化研究
- 批准号:
10588312 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
癌症靶向胶束治疗非肌浸润性膀胱癌的 I 期试验
- 批准号:
10426035 - 财政年份:2020
- 资助金额:
-- - 项目类别:
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
癌症靶向胶束治疗非肌浸润性膀胱癌的 I 期试验
- 批准号:
10578717 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
- 批准号:
10158416 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
靶向纳米卟啉增强膀胱癌的免疫治疗
- 批准号:
9898243 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Targeted-and timed-releasing nanotherapeutics against leukemia stem cells
针对白血病干细胞的靶向定时释放纳米疗法
- 批准号:
10162055 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
针对白血病干细胞的靶向和定时释放纳米疗法
- 批准号:
9260776 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
针对白血病干细胞的靶向和定时释放纳米疗法
- 批准号:
9454297 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Development of targeting nanotherapeutics against bladder cancer
膀胱癌靶向纳米疗法的开发
- 批准号:
8442030 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Development of targeting nanotherapeutics against bladder cancer
膀胱癌靶向纳米疗法的开发
- 批准号:
9275369 - 财政年份:2013
- 资助金额:
-- - 项目类别:
相似海外基金
Living in limbo: The Experience of and Relationship between Fear of Progression, Illness Uncertainty, Symptom Burden, and Death Anxiety in Patients with Advanced or Metastatic Lung Cancer Receiving Immunotherapy or Targeted Therapy
生活在不确定之中:接受免疫治疗或靶向治疗的晚期或转移性肺癌患者对病情进展的恐惧、疾病的不确定性、症状负担和死亡焦虑的经历和关系
- 批准号:
478587 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
TASIS-花生(皮肤内靶向过敏原特异性免疫疗法)贴剂治疗花生过敏的安全性和耐受性
- 批准号:
10551184 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Tumor-Targeted Multimodality Nanoscale Coordination Polymers for Chemo-Immunotherapy of Metastatic Colorectal Cancer
用于转移性结直肠癌化疗免疫治疗的肿瘤靶向多模态纳米配位聚合物
- 批准号:
10639649 - 财政年份:2023
- 资助金额:
-- - 项目类别:
In vivo delivery of Ab-directed CRISPR ribonucleoproteins for anal cancer immunotherapy
用于肛门癌免疫治疗的 Ab 定向 CRISPR 核糖核蛋白的体内递送
- 批准号:
10821884 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Combining immunotherapy with molecularly targeted radiation therapy
免疫治疗与分子靶向放射治疗相结合
- 批准号:
10736873 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
-- - 项目类别:
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
VLA-4™ 靶向 67Cu-LLP2A 预处理增强基于 T 细胞的过继免疫疗法的疗效
- 批准号:
10713034 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy
项目 1:利用 CD11b 激动剂使 PDAC 对免疫疗法产生反应
- 批准号:
10708574 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Sensitization to RIPK1-dependent death as a strategy to enhance response of renal cell carcinoma (RCC) to immunotherapy
对 RIPK1 依赖性死亡的敏感性作为增强肾细胞癌 (RCC) 对免疫治疗反应的策略
- 批准号:
10721156 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeting myeloid cells to increase efficacy of immunotherapy against brain tumors.
靶向骨髓细胞以提高针对脑肿瘤的免疫疗法的功效。
- 批准号:
10571040 - 财政年份:2023
- 资助金额:
-- - 项目类别: